An anti-dizziness and / or anti-fatigue composition, preparation and use thereof

Abstract

This invention provides an anti-vertigo and / or anti-fatigue composition, its formulation, and its application, relating to the field of functional formulation technology. The composition comprises the following components in weight percentages: 0.01%-0.5% turmeric extract, 1%-5% branched-chain amino acids, 0.5%-3% ginger extract, and 0.05%-0.5% oyster peptides. Animal experiments have demonstrated that the composition of this invention can significantly reduce the vertigo response index in rats with motion sickness, prolong weight-bearing swimming time, reduce blood lactate and serum urea nitrogen levels, and increase liver glycogen reserves. Compared with commercially available anti-motion sickness chemical drugs such as dimenhydrinate, this invention achieves anti-vertigo effects without causing a decrease in weight-bearing swimming time and has significant anti-fatigue effects. The composition of this invention is composed of natural raw materials, has high safety, and achieves a synergistic effect of anti-vertigo and anti-fatigue, and can be widely used in the preparation of drugs or health products for the prevention and / or treatment of motion sickness and the relief of physical fatigue.

Description

Technical Field

[0001] This invention belongs to the field of functional formulation technology, specifically an anti-vertigo and / or anti-fatigue composition, its formulation and application. Background Technology

[0002] Motion sickness, a common physiological reaction, is caused by unsuitable motion environment stimulation, leading to a lack of coordination between the vestibular, visual, and proprioceptive systems. Typical symptoms include dizziness, nausea, vomiting, pallor, and cold sweats, severely impacting travel efficiency and quality of life. Simultaneously, dizziness and stress responses such as nausea and vomiting consume significant physical energy and trigger intense mental tension, resulting in significant physiological and psychological fatigue and a decline in overall bodily function. Currently, interventions for motion sickness primarily rely on chemical drugs, such as antihistamines (e.g., dimenhydrinate) and anticholinergics (e.g., scopolamine). These drugs mainly work by inhibiting the excitability of the central nervous system or vestibular system. Although these drugs have shown some effectiveness in controlling the core symptoms of vertigo, their inherent defects are also very prominent: (1) Significant central nervous system side effects: Most drugs are prone to causing adverse reactions such as drowsiness, dry mouth, dizziness, and decreased attention, which seriously affect the safety of users, especially drivers, high-altitude workers and other people who need to maintain a high level of vigilance. (2) Increased fatigue: The sedative effect of many anti-vertigo drugs itself will increase the user's drowsiness and fatigue, which will have a superimposed effect with the fatigue caused by motion sickness itself, which is not conducive to the user maintaining sufficient energy and rapid recovery before and after performing tasks. In view of the above limitations of chemical drugs, the market demand for safe, non-side-effect or minimally side-effect natural functional preparations is becoming increasingly urgent. Ginger, turmeric and other medicinal and edible plants have become important candidate raw materials for the development of anti-vertigo products due to their long history of traditional application and recognized safety. Existing research and some products have also confirmed that ginger extract and other products have certain anti-nausea and antiemetic effects.

[0003] However, the current research and development of anti-vertigo products based on natural ingredients still faces the following key technical problems: (1) Single function: Most existing products only focus on relieving core symptoms such as vertigo and nausea, generally neglecting the improvement effect on physiological fatigue that accompanies or is induced by motion sickness, and lacking a synergistic solution for anti-vertigo and anti-fatigue. (2) Empirical formulation and lack of precise dosage verification: Many traditional formulations rely on experience and lack systematic and precise research based on modern pharmacology and dosage conversion relationships. Whether the ratio between ingredients is optimal, and how the comprehensive effect on vertigo and fatigue at different doses is, lacks sufficient experimental data support, resulting in unstable product efficacy or failure to reach the optimal level.

[0004] Therefore, developing a novel nutritional preparation that can effectively relieve motion sickness symptoms, combat the fatigue they cause, and has no side effects from traditional drugs has significant market value and clinical significance. Summary of the Invention

[0005] In view of this, the object of the present invention is to provide an anti-vertigo and / or anti-fatigue composition, which has a significant anti-fatigue effect while achieving an anti-vertigo effect.

[0006] To achieve the above-mentioned objectives, the present invention provides the following technical solution: The present invention provides an anti-vertigo and / or anti-fatigue composition comprising, by weight percentage, the following components: 0.01%-0.5% turmeric extract, 1%-5% branched-chain amino acids, 0.5%-3% ginger extract, 0.05%-0.5% oyster peptide, with the remainder being excipients.

[0007] Preferably, the branched-chain amino acid is a mixture of L-leucine, L-valine and L-isoleucine in a weight ratio of 2:1:1.

[0008] The present invention also provides a compound preparation for anti-vertigo and / or anti-fatigue, the compound preparation comprising the aforementioned composition and excipients.

[0009] Preferably, the dosage form of the compound preparation includes oral liquid, jelly, capsule, tablet, granule or powder.

[0010] Preferably, the excipients include one or more of the following: white sugar, edible salt, xanthan gum, gelatin, fruit flavoring concentrate, citric acid, and mogroside.

[0011] The present invention also provides a method for preparing the compound preparation, comprising the following steps: thoroughly mixing the composition with excipients, homogenizing, and sterilizing to obtain the compound preparation.

[0012] The present invention also provides the use of the composition or the compound preparation described herein in the preparation of products for the prevention and / or treatment of motion sickness.

[0013] The present invention also provides the use of the composition or the compound preparation described herein in the preparation of products for relieving physical fatigue.

[0014] The present invention also provides the use of the composition or the compound preparation described herein in the preparation of anti-vertigo and anti-fatigue products.

[0015] Preferably, the products used in the application include pharmaceuticals or health supplements.

[0016] Compared with the prior art, the present invention has the following advantages: (1) This invention produces a significant synergistic effect by combining four active ingredients—turmeric extract, branched-chain amino acids, ginger extract, and oyster peptide—in a specific ratio. Animal experiments show that the compound preparation of this invention is significantly superior to the single ginger extract group in reducing the vertigo response index in rats with motion sickness, and significantly superior to the single oyster peptide group in prolonging the weight-bearing swimming time, reducing blood lactate and serum urea nitrogen levels, and increasing liver glycogen reserves. This proves that the components do not simply have superimposed functions, but rather enhance the anti-vertigo and anti-fatigue effects through synergistic effects. Compared with the commercially available anti-vertigo chemical drug dimenhydrinate, the compound preparation of this invention, while achieving a significant anti-vertigo effect, can significantly prolong the weight-bearing swimming time in rats with motion sickness, effectively reduce blood lactate and serum urea nitrogen levels, and increase liver glycogen reserves. From both behavioral and biochemical dimensions, it is confirmed that it has both anti-vertigo and anti-fatigue effects, achieving a synergistic unity of anti-vertigo and anti-fatigue, and solving the technical problem of single function in the prior art.

[0017] (2) The present invention uses natural ingredients that are both food and medicine as active ingredients, such as turmeric extract and ginger extract. It has high safety and does not have the defects of traditional anti-vertigo drugs that cause drowsiness, dry mouth, dizziness and other central nervous system side effects. It provides a safer alternative for people with motion sickness.

[0018] (3) The compound preparation of the present invention can be prepared into various dosage forms such as oral liquid, jelly, capsule, tablet, granule or powder as needed to meet the needs of different groups and usage scenarios. The preparation method of the present invention is simple and easy to industrialize. Through step-by-step addition, mixing, homogenization and sterilization, the active ingredients can be evenly distributed and the quality is stable in the preparation, which has good practicality and operability. Attached Figure Description

[0019] Figure 1 The figure shows the comparison of the motion sickness index (MSI) of rats under different treatment groups. represent P <0.05, represent P <0.01, represent P <0.001; Figure 2 The figures show the results of weighted swimming experiments in rats under different treatment groups. represent P <0.001; Figure 3 The figure shows the results of lactate levels in rats under different treatment groups. represent P <0.01, represent P <0.0001, ns representsP >0.05; Figure 4 The figure shows the results of blood urea nitrogen (BUN) levels in rats under different treatment groups. represent P <0.05, represent P <0.001; Figure 5 The figure shows the results of liver glucose level detection in rats under different treatment groups. represent P <0.05, represent P <0.01. Detailed Implementation

[0020] This invention provides an anti-vertigo and / or anti-fatigue composition, preferably comprising the following components by weight percentage: 0.01%-0.5% turmeric extract, 1%-5% branched-chain amino acids, 0.5%-3% ginger extract, 0.05%-0.5% oyster peptide, with the balance being excipients; more preferably comprising the following components by weight percentage: 0.02%-0.4% turmeric extract, 1.5%-4% branched-chain amino acids, 1%-2% ginger extract, 0.2%-0.4% oyster peptide, with the balance being excipients; and even more preferably comprising the following components by weight percentage: 0.026% turmeric extract, 2% branched-chain amino acids, 1.23% ginger extract, 0.249% oyster peptide, with the balance being excipients. The turmeric extract is an extract rich in curcuminoids obtained from turmeric rhizomes, wherein the curcumin content of the turmeric extract is between 10% and 95%, and it is obtainable through conventional commercial channels. In a specific embodiment of the present invention, the turmeric extract used is a turmeric extract with 95% curcumin content purchased from Nanjing Zelang Biotechnology Co., Ltd.; the branched-chain amino acids are a mixture of L-leucine, L-valine, and L-isoleucine, preferably in a weight ratio of 2:1:1. The branched-chain amino acid raw materials used in the present invention are purchased from Jiangsu Jiayuancheng Biotechnology Co., Ltd. The ginger extract is a product obtained from ginger as raw material through an extraction process, wherein the 6-gingerol content is usually not less than 5%. In a specific embodiment of the present invention, the ginger extract is a 10:1 concentrated extract (i.e., 1 kg of extract is obtained from 10 kg of ginger raw material), with a fineness of 80 mesh, purchased from Nanjing Zelang Biotechnology Co., Ltd. This specification of ginger extract is a conventional commercially available product in the field, and its 6-gingerol and other active ingredient content meets industry standards. The oyster peptides are a mixture of small molecule peptides obtained by enzymatic hydrolysis and purification of oyster protein, with a molecular weight usually less than 1000 Daltons and a peptide content of not less than 80%, which can also be obtained through conventional commercial channels. In a specific embodiment of the present invention, the oyster peptide was purchased from Nanjing Zelang Biotechnology Co., Ltd. In the present invention, the excipients include, but are not limited to, pharmaceutically or food-acceptable carriers, excipients, or additives such as water, white sugar, orange puree, xanthan gum, gelatin, citric acid, mogrosides, and edible salt.

[0021] This invention also provides a compound formulation for anti-vertigo and / or anti-fatigue, the compound formulation comprising the aforementioned composition and excipients. Preferably, the compound formulation consists of the aforementioned composition and pharmaceutically or food-acceptable excipients, wherein the composition is a combination of active ingredients as defined in this invention, comprising a specific weight percentage of turmeric extract, branched-chain amino acids, ginger extract, and oyster peptides. The selection of excipients depends on the desired dosage form and the intended use of the formulation, and may include, but is not limited to, fillers, binders, flavoring agents, colorants, thickeners, gelling agents, emulsifiers, stabilizers, preservatives, and solvents, as commonly used excipient types in the art. When preparing oral liquid formulations, water can be used as a solvent, and flavoring agents such as granulated sugar and orange puree can be added to improve the taste. Thickeners such as xanthan gum can be added to adjust the viscosity and stability of the formulation. When preparing jelly-like semi-solid formulations, gelling agents can be added to form a suitable gel state. When preparing solid formulations such as capsules, tablets, or granules, fillers such as microcrystalline cellulose, starch, and lactose, as well as lubricants such as magnesium stearate, can be used, and the formulation can be produced through conventional granulation, tableting, or filling processes. The preparation method of the compound formulation typically includes thoroughly mixing, dissolving, or dispersing the composition with the selected excipients, followed by homogenization, filling, sterilization or drying, and molding according to the dosage form requirements, ultimately obtaining the finished formulation. By selecting different excipients and formulation processes, the compound formulation of this invention can be made into various dosage forms such as oral liquids, jellies, capsules, tablets, granules, or powders to meet the consumption needs and usage scenarios of different populations. In this invention, the excipients are selected from one or more of the following: granulated sugar, edible salt, xanthan gum, gelatin, fruit flavoring concentrate, citric acid, and mogroside. The gelatin is prepared by mixing konjac flour and carrageenan in a 1:1 ratio. The fruit flavoring concentrate preferably includes, but is not limited to, orange concentrate, strawberry concentrate, passion fruit concentrate, hawthorn concentrate, and lemon concentrate. The types and amounts of these excipients can be determined by those skilled in the art based on conventional knowledge, and their addition does not affect the anti-vertigo and anti-fatigue effects of the composition itself.

[0022] This invention also provides a method for preparing the compound preparation, preferably comprising the following steps: thoroughly mixing the composition with excipients, homogenizing, and sterilizing to obtain the compound preparation. As a preferred embodiment, the composition and excipients are first thoroughly mixed. This mixing process can be carried out gradually according to the properties of the materials. For example, ginger extract, branched-chain amino acids, and some excipients such as white sugar (dry powder) are initially mixed. Then, components such as oyster peptides and turmeric extract, which are used in smaller quantities or are prone to clumping, are placed in a container and pre-mixed by turning the container upside down. Finally, all materials are mixed a second time to ensure that the active ingredients are evenly distributed in the preparation. Subsequently, the evenly mixed materials are homogenized. This step is particularly important for preparing liquid preparations such as oral liquids and jellies. Homogenization under appropriate pressure using a homogenizer can fully disperse the components in the system, preventing particle sedimentation or aggregation, thereby obtaining a product with a uniform state and a smooth texture. Finally, the homogenized or shaped formulation is sterilized. The sterilization method can be selected according to the characteristics of the formulation. For example, water bath sterilization or high-temperature instantaneous sterilization can be used for liquid formulations, while irradiation sterilization or other suitable methods can be used for solid formulations. The sterilization conditions must ensure that the product meets the microbial limit requirements without compromising the stability of the active ingredients. Through the above steps, a stable and effective anti-vertigo and / or anti-fatigue compound formulation can be obtained. This preparation method is simple and easy to industrialize.

[0023] The present invention also provides the use of the composition or the compound preparation described herein in the preparation of products for the prevention and / or treatment of motion sickness.

[0024] The present invention also provides the use of the composition or the compound preparation described herein in the preparation of products for relieving physical fatigue.

[0025] The present invention also provides the use of the composition or the compound preparation described herein in the preparation of anti-vertigo and anti-fatigue products.

[0026] In this invention, the products used in the application preferably include pharmaceuticals or health products.

[0027] The technical solutions provided by the present invention will be described in detail below with reference to the embodiments, but they should not be construed as limiting the scope of protection of the present invention.

[0028] Unless otherwise specified, the experimental methods used in the following embodiments are conventional methods. Unless otherwise specified, the experimental materials used in the following embodiments are commercially available products.

[0029] Example 1 An anti-vertigo and / or anti-fatigue composition comprising, by weight percentage, the following components: 0.03% turmeric extract, 1.0% L-leucine, 0.5% L-valine, 0.5% L-isoleucine, 1.24% ginger extract, 0.25% oyster peptide, with the balance being excipients.

[0030] Example 2 An anti-vertigo and / or anti-fatigue composition comprising, by weight percentage, the following components: 0.01% turmeric extract, 0.5% L-leucine, 0.25% L-valine, 0.25% L-isoleucine, 0.5% ginger extract, 0.05% oyster peptide, with the remainder being excipients.

[0031] Example 3 An anti-vertigo and / or anti-fatigue composition comprising, by weight percentage, the following components: turmeric extract 0.3%, L-leucine 2.0%, L-valine 1.0%, L-isoleucine 1.0%, ginger extract 2.0%, oyster peptide 0.4%, with the remainder being excipients.

[0032] Example 4 An anti-vertigo and / or anti-fatigue beverage, based on the preparation of 100ml of beverage, comprises the following ingredients: 1.23g ginger extract, 1.0g L-leucine, 0.5g L-valine, 0.5g L-isoleucine, 1.23g white sugar, 0.249g oyster peptide, 0.026g turmeric extract, 0.083g citric acid, 0.066g mogroside, 0.3g xanthan gum, 13.64g orange puree, and 81.176g drinking water.

[0033] The preparation method of the above beverage is as follows: (1) Mixing stage First, ginger extract, L-leucine, L-valine, L-isoleucine, and white sugar are initially mixed to obtain a mixture A of five raw materials.

[0034] Take four raw materials: oyster peptide, citric acid, mogroside, and turmeric extract, and place them in a PE bag with an equal weight of the mixture A of the five raw materials. Complete 15 cycles of mixing by flipping the bag up and down to obtain premix B.

[0035] The premix B is mixed a second time with the remaining five raw material mixture A to form a complete mixture C.

[0036] (2) Sol stage Add xanthan gum to purified water at 60±5℃ and stir until completely dissolved to obtain glue solution D. Add mixture C to glue solution D and mix thoroughly until completely dissolved.

[0037] (3) Homogenization Orange puree was added to the sol-gel mixture and homogenized using a homogenizer.

[0038] (4) Filling and Packaging The homogenized material is quantitatively filled into containers in 100ml increments, and the caps are screwed on immediately after filling.

[0039] (5) Sterilization and packaging The packaged product is sterilized by water bath sterilization, and then labeled to obtain the finished compound beverage of this invention.

[0040] Example 5 An anti-vertigo and / or anti-fatigue jelly, with the following raw material composition per 100g of jelly: 1.23g ginger extract, 1.0g L-leucine, 0.5g L-valine, 0.5g L-isoleucine, 0.88g white sugar, 0.249g oyster peptide, 0.1g edible salt, 0.026g turmeric extract, 0.06g citric acid, 0.03g mogroside, 0.75g jelly gelatin (konjac powder: carrageenan = 1:1), 13.72g orange puree, and 80.955g water.

[0041] The preparation method of the above-mentioned jelly is as follows: (1) Mixing stage First, ginger extract, L-leucine, L-valine, L-isoleucine, and white sugar are initially mixed to obtain a mixture A of five raw materials.

[0042] Take five raw materials: oyster peptide, edible salt, turmeric extract, citric acid, and mogroside, and place them in a PE bag with an equal weight of the mixture A of the five raw materials. Complete 15 cycles of mixing by flipping the bag over to obtain premix B.

[0043] The premix B is mixed a second time with the remaining five raw material mixture A to form a complete mixture C.

[0044] (2) Sol stage Add the gelatin to purified water at 60±5℃ and stir until completely dissolved to obtain gel solution D. Add the mixture C to gel solution D and mix thoroughly until completely dissolved.

[0045] (3) Homogenization Orange puree was added to the sol-gel mixture and homogenized using a homogenizer.

[0046] (4) Filling and Packaging The homogenized material is hot-filled in 100g portions, and capping is performed immediately after filling.

[0047] (5) Sterilization and packaging The packaged product is sterilized by water bath sterilization, cooled and shaped after sterilization, and then labeled to obtain the compound jelly product of this invention.

[0048] Example 6: Pharmacodynamic experiments of the anti-vertigo and / or anti-fatigue composition of the present invention 1. Grouping and administration of experimental animals Sixty-four male SD rats, aged 10 weeks and weighing 320-390g, were purchased from Shanghai Jiesijie Laboratory Animal Co., Ltd. Grouping and treatment methods are shown in Table 1. Rats were randomly divided into eight groups using a random number table: control group (CON group), motion sickness group (MS group), low-dose group (LOW group), high-dose group (HIGH group), single ginger extract group (GE group), single oyster peptide group (OP group), ginger-free group (NG group), and commercially available chemical-dimenhydrinate group (DMH group). The motion sickness model was established in the motion sickness group by subjecting them to rotational acceleration stimulation for 2 hours. The control group was placed under the same static conditions, and the motion sickness response index (piloerection, tremor, urination, defecation, etc.) was calculated.

[0049] Table 1 Grouping and Processing Methods

[0050] 2. Dosage design and optimization To determine the dosage of the composition of Example 1 of the present invention in animal experiments, the equivalent dose for rats was first calculated based on the recommended daily intake of each component for humans, combined with the conversion factor of body surface area between rats and humans (taken as 6.2), and then a dose five times that was set as the theoretical low dose.

[0051] Taking turmeric extract as an example, the recommended daily intake for humans is 50 mg / 60 kg person / day (i.e., 0.83 mg / kg). Therefore, the equivalent dose (theoretical low dose) in rats is 0.83 mg / kg × 6.2 = 5.1 mg / kg (based on pure curcumin), and the theoretical high dose is 5.1 mg / kg × 5 = 25.5 mg / kg (based on pure curcumin). Considering that the curcumin content in turmeric extract is 95%, the actual dosage of turmeric extract is approximately 5.1 mg / kg ÷ 0.95 ≈ 5.4 mg / kg (low dose) and 25.5 mg / kg ÷ 0.95 ≈ 26.8 mg / kg (high dose).

[0052] The theoretical doses of branched-chain amino acids, ginger extract, and oyster peptides were calculated using the same method, and the results were as follows: theoretical low dose of branched-chain amino acids was 413.5 mg / kg, and theoretical high dose was 2067.5 mg / kg; theoretical low dose of ginger extract was 5.1 mg / kg, and theoretical high dose was 25.5 mg / kg; theoretical low dose of oyster peptides was 51.6 mg / kg, and theoretical high dose was 258 mg / kg.

[0053] Preliminary experiments revealed that direct administration of the theoretically calculated dose caused adverse reactions such as vomiting in rats, indicating that the dose was too high. To ensure animal welfare and obtain stable and reliable pharmacodynamic data, the doses were adjusted: the theoretically calculated dose was reduced to half of the original dose for the low-dose group in the formal experiment, and the dose was reduced to one-fifth of the original dose for the high-dose group. The adjusted actual dosages are shown in Table 2. Table 2. Dosage of each component in rats administered via gavage at low and high doses.

[0054] 3. Establishment of a rat model of motion sickness A rat model of motion sickness was established using a rotational stimulation device. Rats were placed in four-compartment containers with holes, one rat per compartment. Rats in the rotational acceleration stimulation group were placed on the rotational stimulation device. After the containers were securely fixed, they were rotated bidirectionally along a horizontal axis at varying speeds, initially at 16° / s. 2 After accelerating with angular acceleration to reach a maximum speed of 120° / s, it immediately accelerates at 48° / s. 2 Decelerate, stop, and repeat the same movement in the opposite direction, with each cycle lasting 10 seconds. The stimulation duration is 2 hours. Immediately after receiving the rotational acceleration stimulation, observe the amount of feces, whether urination occurs, and whether tremors and prickling occur, and calculate the Motion Response Index (MSI) score. The MSI scoring criteria are as follows: Table 3 MSI Scoring Criteria

[0055] 4. Detection indicators (1) Weighted swimming experiment The rat weight-bearing swimming test is a commonly used method to assess an animal's fatigue resistance and exercise endurance. Thirty minutes after the last drug administration, rats with a lead weight of 5% of their body weight loaded at the base of their tails are placed in a swimming tank with a water depth of 35 cm and a water temperature controlled at (25±1.0)℃. Throughout the experiment, each rat's limbs are kept in motion, and they are propelled to swim continuously with a wooden stick. The criterion for determining the outcome is whether the rat remains submerged for 7 seconds after sinking. The duration of this swimming test is recorded as the rat's weight-bearing swimming time.

[0056] (2) Determination of serum urea nitrogen and lactate: Thirty minutes after the last administration, SD rats were generally anesthetized by intraperitoneal injection of 3% sodium pentobarbital (0.2 ml / 100 g body weight) at a dose of 30 mg / kg body weight. After the rats were deeply anesthetized and their bodies were softened, they were fixed in a supine position, and blood was collected from the abdominal aorta. The blood was left to stand for 3 hours and then irradiated at 3000 rpm. -1 Serum was separated by centrifugation for 15 min and stored at -80℃ for later use. Serum urea nitrogen and lactate levels in each group of rats were then measured strictly according to the standard operating procedure of the kit.

[0057] (3) Measurement of liver glycogen reserve level Animals were sacrificed 30 minutes after the last administration, and rat liver tissue was collected. The liver tissue was rinsed with pre-cooled physiological saline, blotted dry with filter paper, and then frozen in liquid nitrogen at -80°C for later use. Serum liver glycogen reserve levels in each group of rats were then measured strictly according to the standard operating procedure of the kit.

[0058] 5. Experimental Results (1) Effects of different groups on the motion sickness response index of rats with motion sickness like Figure 1 As shown, compared with the control group (CON), the motion sickness response index (MSI) of the motion sickness group (MS) was significantly higher. P <0.05 indicates that the motion sickness model was successfully established. The MSI of both the (LOW) and high-dose (HIGH) groups of this invention was significantly lower than that of the MS group (…). P <0.05、 P <0.01 indicates that the composition of the present invention can significantly alleviate motion sickness symptoms; compared with the single ginger extract group (GE) and the single oyster peptide group (OP), the MSI of the LOW and HIGH groups was lower, demonstrating that the combination of turmeric extract, branched-chain amino acids (BCAA), oyster peptide and ginger extract produced a synergistic anti-vertigo effect. Compared with the ginger-removed group (NG), the MSI of the LOW and HIGH groups was significantly reduced ( P <0.05), proving that ginger extract is the key component in the composition of the present invention that exerts the anti-vertigo effect, and the anti-vertigo effect is significantly reduced after removal; compared with the commercially available chemical drug dimenhydrinate (DMH), the MSI of the LOW and HIGH groups is lower, indicating that the anti-vertigo effect of the composition of the present invention is better than that of existing commercially available anti-motion sickness drugs.

[0059] (2) Effects of different intervention groups on swimming time under load and exhaustion in rats with motion sickness Rats underwent a weighted swimming behavioral experiment after the rotational acceleration stimulus was completed. The results of the behavioral experiment are as follows: Figure 2 As shown, compared with the CON group, the MS group rats had a significantly shorter weight-bearing swimming time ( P<0.001, suggesting that motion sickness stimulation can lead to a decrease in physical reserves and a weakened ability to resist fatigue in rats. The swimming time in both the LOW and HIGH groups was significantly longer than that in the MS group ( P <0.001 indicates that the composition of the present invention can significantly improve physical weakness caused by motion sickness and enhance anti-fatigue ability. Compared with the DMH group, the swimming time of the LOW and HIGH groups was significantly longer ( P <0.001 indicates that traditional anti-motion sickness chemicals (dimenhydrinate) are ineffective in relieving fatigue and may even worsen it. In contrast, the composition of this invention significantly improves exercise endurance while combating vertigo, achieving a synergistic dual effect of anti-vertigo and anti-fatigue. Compared to the GE and OP groups, the LOW and HIGH groups had significantly longer swimming times. P The result of <0.001 further confirms that the synergistic effect of the compound components is superior to that of the single components.

[0060] (3) Effects of different groups on biochemical indicators of rats like Figure 3 The results showed that, compared with the CON group, the serum lactate level in the MS group was significantly higher ( P <0.01 indicates that motion sickness stimulation leads to lactic acid accumulation and the accumulation of fatigue metabolites. Lactate levels in the LOW and HIGH groups were significantly lower than those in the MS group ( P <0.0001 indicates that the composition of the present invention can effectively remove lactic acid and reduce the accumulation of fatigue metabolites. Compared with the GE group and the OP group, the lactic acid levels in the LOW group and the HIGH group were significantly lower ( P <0.0001), indicating that the compound has a better synergistic effect on lactate clearance than the single component. There was no significant difference in lactate levels between the DMH group and the MS group (ns, P >0.05), indicating that commercially available chemical drugs cannot improve lactic acid metabolism, while the composition of the present invention has unique advantages in regulating energy metabolism and relieving fatigue.

[0061] according to Figure 4 The results showed that, compared with the CON group, the serum urea nitrogen level in the MS group was significantly higher ( P <0.001 indicates that motion sickness stimulation leads to increased protein breakdown and a heavier metabolic burden on the body. The urea nitrogen levels in the LOW and HIGH groups were significantly lower than those in the MS group ( P <0.05 indicates that the compound of this invention can effectively reduce protein breakdown and alleviate fatigue-induced damage to the body. Compared with the GE and OP groups, the LOW and HIGH groups had significantly lower urea nitrogen levels ( P <0.05, further confirming that the synergistic protective effect of the compound is superior to that of the single component. The urea nitrogen level in the DMH group was significantly higher than that in the LOW group ( PThe concentration of urea nitrogen (BUN) <0.05 indicates that commercially available chemical drugs cannot improve protein metabolism, while the compound formula of this invention can effectively protect the body's metabolic homeostasis. The NG group had a higher BUN nitrogen level than the LOW group, indicating that ginger extract plays an important role in protecting protein metabolism.

[0062] according to Figure 5 The results showed that, compared with the CON group, the MS group had significantly lower liver glycogen levels ( P <0.01 indicates that motion sickness stimulation leads to increased liver glycogen consumption and insufficient energy reserves. The liver glycogen levels in the LOW and HIGH groups were significantly higher than those in the MS group ( P <0.05 indicates that the compound formula of this invention can effectively increase liver glycogen reserves, providing the body with a more sufficient energy source, which is an important material basis for its anti-fatigue effect. Compared with the GE group and OP group, the liver glycogen levels of the LOW group and HIGH group were significantly higher ( P <0.05 indicates that the compound has a better synergistic effect on improving energy reserves than the single component. The liver glycogen level in the DMH group was significantly lower than that in the LOW group ( P The concentration of glycogen in the NG group was <0.05%, indicating that commercially available chemical drugs cannot improve energy reserves, while the compound formula of this invention can effectively enhance the body's energy supply capacity. The liver glycogen level in the NG group was lower than that in the LOW group, suggesting that ginger extract plays an important role in improving liver glycogen reserves.

[0063] The above description is only a preferred embodiment of the present invention. It should be noted that for those skilled in the art, several improvements and modifications can be made without departing from the principle of the present invention, and these improvements and modifications should also be considered within the scope of protection of the present invention.

Claims

1. A composition for relieving dizziness and / or fatigue, characterized in that, The composition comprises, by weight percentage, the following components: turmeric extract 0.01%-0.5%, branched-chain amino acids 1%-5%, ginger extract 0.5%-3%, oyster peptide 0.05%-0.5%, with the remainder being excipients.

2. The composition according to claim 1, characterized in that, The branched-chain amino acids are composed of L-leucine, L-valine and L-isoleucine in a weight ratio of 2:1:

1.

3. A compound preparation for relieving dizziness and / or fatigue, characterized in that, The compound preparation includes the composition according to claim 1 or 2 and excipients.

4. The compound preparation according to claim 3, characterized in that, The dosage forms of the compound preparation include oral liquid, jelly, capsule, tablet, granule or powder.

5. The compound preparation according to claim 3, characterized in that, The excipients include one or more of the following: white sugar, edible salt, xanthan gum, gelatin, fruit flavoring concentrate, citric acid, and mogroside.

6. The method for preparing the compound preparation according to any one of claims 3-5, characterized in that, The process includes the following steps: thoroughly mixing the composition with excipients, homogenizing, and sterilizing to obtain the compound preparation.

7. The use of the composition of claim 1 or 2, or the compound preparation of any one of claims 3-4, in the preparation of products for the prevention and / or treatment of motion sickness.

8. The use of the composition according to claim 1 or 2, or the compound preparation according to any one of claims 3-4, in the preparation of products for relieving physical fatigue.

9. The use of the composition according to claim 1 or 2, or the compound preparation according to any one of claims 3-4, in the preparation of anti-vertigo and anti-fatigue products.

10. The application according to any one of claims 7-9, characterized in that, The products used in this application are medicines or health supplements.

Images